Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma's Board, at its meeting on February 12, 2026, approved the incorporation of a wholly owned subsidiary in Chile named NATCO Pharma Chile SPA. The proposed investment is up to US$300,000 (approximately ₹2.5 crore) in cash, with Natco Pharma holding 100% equity. The subsidiary will operate in the pharmaceuticals sector and is subject to FEMA and local Chilean regulatory approvals. The entity is yet to be incorporated and the move appears aimed at expanding the company's international footprint in Latin America.
The investment size is very small relative to Natco Pharma's overall scale, so the immediate financial impact is minimal. However, it signals the company's intent to expand into the Chilean/Latin American pharma market, which could open up new revenue streams over the long term.